Herbalife Ltd header image

Herbalife Ltd

HLF

Equity

ISIN KYG4412G1010 / Valor 2002103

CTA NASDAQ OMX Stock Exchange (2025-11-20)
USD 9.64+4.56%

Herbalife Ltd
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Herbalife Ltd. is a global nutrition company that operates primarily through a direct selling model, offering a range of products in areas such as weight management, sports nutrition, energy, and performance supplements. The company distributes its products via an extensive network of independent distributors across international markets, a model that emphasizes close ties with its consumer base. In recent years, the firm's leadership has focused on modernizing its sales training, deepening distributor engagement, and establishing strategic partnerships, all while transitioning toward a more agile, technology-driven global wellness platform. This strategic shift, led by Stephan Gratziani—who rose from a top-performing distributor to CEO—reflects the company's effort to maintain its long-term growth trajectory while adapting to evolving market dynamics.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (12.10.2025):

Herbalife Ltd. reported its financial results for the second quarter of 2025, achieving net sales of $1.3 billion near the midpoint of guidance. The company's adjusted EBITDA1 exceeded expectations, and it has raised its full-year net sales and adjusted EBITDA1 guidance. Additionally, Herbalife launched its MultiBurn™ supplement and unveiled the beta version of its Pro2col™ app alongside a healthy lifespan supplement.

Net Sales Near Guidance Midpoint

For Q2 2025, Herbalife Ltd. reported net sales of $1.3 billion, aligning closely with the midpoint of the company’s guidance range. On a constant currency basis, net sales remained flat year-over-year, despite a 1.7% decline in reported sales due to foreign currency headwinds.

Adjusted EBITDA1 Exceeds Guidance

Herbalife achieved an adjusted EBITDA1 of $173.6 million in Q2 2025, surpassing guidance expectations. The adjusted EBITDA1 margin stood at 13.8%, although it decreased by 30 basis points compared to Q2 2024.

Raised Full-Year Guidance

The company has elevated its full-year 2025 guidance, increasing both net sales and adjusted EBITDA1 projections. Capital expenditures have been reduced, reflecting Herbalife’s commitment to financial discipline and long-term growth.

Innovative Product Launches

In July 2025, Herbalife launched MultiBurn™, a new weight-loss supplement, and unveiled the beta version of its AI-assisted Pro2col™ digital platform. Additionally, the company introduced a healthy lifespan supplement at the North America Extravaganza, engaging over 7,000 distributors in the initial beta release.

Summarized from source with an LLMView Source

Key figures

14.6%1Y
-40.6%3Y
-80.0%5Y

Performance

66.8%1Y
64.3%3Y
57.7%5Y

Volatility

Market cap

994 M

Market cap (USD)

Daily traded volume (Shares)

2,924,466

Daily traded volume (Shares)

1 day high/low

6.83 / 6.6

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Dermapharm Holding SE
Dermapharm Holding SE Dermapharm Holding SE Valor: 40166352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.42%EUR 35.45
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.60%CHF 95.34
Tecan Group Ltd.
Tecan Group Ltd. Tecan Group Ltd. Valor: 1210019
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.30%CHF 133.00
Siegfried Holding Ltd
Siegfried Holding Ltd Siegfried Holding Ltd Valor: 1428449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.59%CHF 70.10
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.97%CHF 67.40
medmix Ltd
medmix Ltd medmix Ltd Valor: 112967710
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.83%CHF 8.34
Fagron SA
Fagron SA Fagron SA Valor: 3425437
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.74%EUR 20.50
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.12%DKK 577.00
Ardent Health Partners Inc
Ardent Health Partners Inc Ardent Health Partners Inc Valor: 136301364
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%USD 8.64
H. Lundbeck A/S
H. Lundbeck A/S H. Lundbeck A/S Valor: 119252587
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.05%DKK 44.14